TRANSFORM

  • TRANSFORM Position on the EU Pharmaceutical Package

    TRANSFORM Alliance Members’ consensus positions in response the European Commission’s legislative proposals on the Pharmaceutical Package. These positions aim to drive positive change across the full lifecycle of ATMPs, hence they are listed according to their place in the lifecycle of a therapy, from research through to patient access, and must be viewed holistically.

    More →

  • TRANSFORM MEP Charter with Solutions to Enable Safe and Timely Patient Access to Advanced Therapies in Europe

    On 13 October, the European Alliance for Transformative Therapies launched its MEP Charter with Solutions to Enable Safe and Timely Patient Access to Advanced Therapies in Europe, developed collaboratively with expert stakeholders. The Charter will serve as a guide for TRANSFORM’s action in the coming years, including for the MEPs to prepare the discussion of expected legislative files such as SoHO legislation, the General Pharmaceuticals legislations, the EHDS, among others.

    More →

  • TRANSFORM: Multi-stakeholder approach to gene and cell therapies

    TRANSFORM is a multi-stakeholder alliance composed of patient groups, medical experts and associations, healthcare and non-healthcare specialists, scientists, researchers, industry actors and other relevant stakeholders. We advocate for improving the regulatory and legislative systems with the intention to realise the promise of transformative therapies for severe, disabling or life-limiting conditions.

    About Us Contact Us

  • Policy Asks on the Regulatory Framework for ATMPs

    The European Alliance for Transformative Therapies’ (TRANSFORM) Policy Asks advocate for a regulatory framework that enables safe and timely patient access to transformative therapies, building on the 2021 TRANSFORM Recommendations for Action. 

    Read Policy Asks

  • Policy Asks on Access to Authorised ATMPs

    The European Alliance for Transformative Therapies’ (TRANSFORM) Policy Asks advocate for changes that offer potential solutions to unlock safe and timely patient access to authorised ATMPs in Europe, building on the 2021 TRANSFORM Recommendations for Action.

    Read Policy Asks

  • 5 Policy Asks to Optimize Cross-border Patient Access to Transformative Therapies

    The TRANSFORM MEP Interest Group launched 5 Policy Asks on how to optimize cross-border patient access to transformative therapies at their online event on 10 November 2021.

    Read Policy Asks Watch Event

Next Event See all →

MEP Interest Group 2023 Conference

COUNTDOWN TO EU ELECTIONS: How can policymakers secure the promise of Advanced Therapies for patients over the next 6 months?
12 October 2023
10h00 - 12h15 CET
Altiero Spinelli Building (Room 5B1), European Parliament, Brussels
The current mandate of the European Parliament is ending, with elections in June 2024. This gives MEPs little more than six months to work on outstanding files. The Parliament is currently reviewing several health legislative proposals that will impact the ATMP ecosystem, including: the Regulation on Substances of Human Origin (SoHO), crucial for products derived from human substances; the European Health Data Space (EHDS), a cornerstone of a new era of digital health, interoperability and innovation; and the proposed Pharmaceutical Package, which contains rules that impact every stage of product development, from R&D to access. Together, they present an opportunity to future-proof healthcare systems and strengthen patients’ access to care by ensuring the EU is attractive for R&D and, therefore, new therapies. The TRANSFORM MEP Interest Group is pleased to host this timely event, together with the TRANSFORM multi-stakeholder Alliance, to explore how policymakers can ensure innovative therapies are a cornerstone of EU healthcare for the future. Registration is subject to approval by the TRANSFORM Secretariat due to limited spaces.
More →

Members

European Society of Gene and Cell Therapy (ESGCT)
ReNEW Consortium – Stem Cell Medicine
EFNA – European Federation of Neurological Associations
RI – Retina International
WDO – World Duchenne Organization
IPOPI – International Patient Organisation for Primary Immunodeficiencies
TIF – Thalassaemia International Federation
EHC – European Haemophilia Consortium
EURORDIS – Rare Diseases Europe
EPTRI – European Paediatric Translational Research Infrastructure
CCI Europe – Childhood Cancer International Europe
SIOP Europe – the European Society for Paediatric Oncology
EAHAD – European Association for Haemophilia and Allied Disorders
EU EYE – European Alliance for Vision Research and Ophthalmology
EUCOPE – European Confederation of Pharmaceutical Entrepreneurs

@TRANSFORM_CGT on Twitter Follow us →

01 January at 12:00am
Reply Retweet